Nageatte Ibrahim
YOU?
Author Swipe
View article: Figure S2 from Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Figure S2 from Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules Open
Figure S2
View article: Figure S1 from Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Figure S1 from Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules Open
Figure S1
View article: Data from Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Data from Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules Open
Purpose:Standard-dose pembrolizumab plus alternative-dose ipilimumab (1 mg/kg Q3W for 4 doses) were tolerable and had robust antitumor activity in advanced melanoma in cohort B of the phase 1 KEYNOTE-029 study. Cohort C evaluated standard-…
View article: Supplementary Data from Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Supplementary Data from Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules Open
Clean version
View article: Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma Open
We conducted a randomized phase III trial to evaluate whether adjuvant pembrolizumab for one year (647 patients) improved recurrence-free survival (RFS) or overall survival (OS) in comparison with high-dose IFNα-2b for one year or ipilimum…
View article: Supplementary Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Supplementary Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma Open
Supplementary Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
View article: Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma Open
We conducted a randomized phase III trial to evaluate whether adjuvant pembrolizumab for one year (647 patients) improved recurrence-free survival (RFS) or overall survival (OS) in comparison with high-dose IFNα-2b for one year or ipilimum…
View article: Supplementary Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Supplementary Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma Open
Supplementary Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
View article: Supplementary Table 3 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Supplementary Table 3 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma Open
PDF file - 39K, Summary of grade 3 and grade 4 events incidence at each dose level for all events and those events possibly, probably, or definitively related.
View article: Supplementary Figure 6 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Supplementary Figure 6 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma Open
PDF file - 82K, Response kinetics in treated patients. Baseline tumor measurements are standardized to zero. A. Entire treatment population (cohorts 1-4). B. Cohort 2 patients (MTD). Horizontal line PD = progressive disease representing 20…
View article: Supplementary Table 4 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Supplementary Table 4 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma Open
PDF file - 43K, Best overall response in ipilimumab plus bevacizumab treated patients per RECIST criteria by treatment cohort.
View article: Supplementary Methods from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Supplementary Methods from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma Open
PDF file - 813K, Appendix A: Clinical Protocol
View article: Data from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Data from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma Open
Ipilimumab improves survival in advanced melanoma and can induce immune-mediated tumor vasculopathy. Besides promoting angiogenesis, vascular endothelial growth factor (VEGF) suppresses dendritic cell maturation and modulates lymphocyte en…
View article: Supplementary Figure 4 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Supplementary Figure 4 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma Open
PDF file - 125K, Individual response of CCR7+CD45RO+ and CCD7-CD45RO+ of CD4+ and CD8+ T cells in melanoma patients treated with ipilimumab (3mg/kg), ipilimumab (3mg/kg) plus bevacizumab, or ipilimumab (10mg/kg) plus bevacizumab.
View article: Supplementary Table 4 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Supplementary Table 4 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma Open
PDF file - 43K, Best overall response in ipilimumab plus bevacizumab treated patients per RECIST criteria by treatment cohort.
View article: Supplementary Figure Legends from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Supplementary Figure Legends from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma Open
PDF file - 59K
View article: Supplementary Figure 2 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Supplementary Figure 2 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma Open
PDF file - 74K, High-power H&E and CD31 stained post treatment biopsy of intratumoral vessels. The endothelial cells appear morphologically columnar. CD31 staining is concentrated at the interendothelial junctions (arrows).
View article: Supplementary Figure 3 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Supplementary Figure 3 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma Open
PDF file - 64K, Illustrations of the variation in pathologic responses to treatment. Examples of intermediate and no response.
View article: Supplementary Figure 3 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Supplementary Figure 3 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma Open
PDF file - 64K, Illustrations of the variation in pathologic responses to treatment. Examples of intermediate and no response.
View article: Supplementary Figure 5 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Supplementary Figure 5 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma Open
PDF file - 68K, A. Axial CT section of the chest at baseline demonstrates two nodules in the right lung, the dominant one in the lower lobe (white arrows). B. Follow-up CT 3 months after start of treatment demonstrates resolution of one of…
View article: Supplementary Figure Legends from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Supplementary Figure Legends from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma Open
PDF file - 59K
View article: Supplementary Figure 2 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Supplementary Figure 2 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma Open
PDF file - 74K, High-power H&E and CD31 stained post treatment biopsy of intratumoral vessels. The endothelial cells appear morphologically columnar. CD31 staining is concentrated at the interendothelial junctions (arrows).
View article: Supplementary Figure 4 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Supplementary Figure 4 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma Open
PDF file - 125K, Individual response of CCR7+CD45RO+ and CCD7-CD45RO+ of CD4+ and CD8+ T cells in melanoma patients treated with ipilimumab (3mg/kg), ipilimumab (3mg/kg) plus bevacizumab, or ipilimumab (10mg/kg) plus bevacizumab.
View article: Supplementary Figure 7 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Supplementary Figure 7 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma Open
PDF file - 59K, Kaplan-Meier estimates for time-to-progression in the entire treated population (A) and by treatment cohort (B). Kaplan-Meier estimates for overall survival in the entire treated population (C) and by treatment cohort (D).
View article: Supplementary Methods from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Supplementary Methods from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma Open
PDF file - 813K, Appendix A: Clinical Protocol
View article: Supplementary Table 2 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Supplementary Table 2 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma Open
PDF file - 139K, Worst grade adverse event for individual patients that occurred within the first twelve weeks of treatment (induction dose-limiting toxicity period). Adverse events recorded multiple times for any patient are reported only…
View article: Supplementary Table 3 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Supplementary Table 3 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma Open
PDF file - 39K, Summary of grade 3 and grade 4 events incidence at each dose level for all events and those events possibly, probably, or definitively related.
View article: Supplementary Table 1 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Supplementary Table 1 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma Open
PDF file - 111K, Patient Demographics.